Nutriband Inc. Advances Toward FDA Approval for AVERSA(TM) Fentanyl Abuse-Deterrent Patch

Nutriband Inc. (NASDAQ: NTRB), a company at the forefront of developing prescription transdermal pharmaceutical products, has reached a pivotal milestone in its quest to combat opioid abuse. The U.S. Food and Drug Administration (FDA) has scheduled a Type C Meeting for September 18, 2025, to evaluate the Chemistry, Manufacturing, and Controls (CMC) plans for Nutriband's flagship product, AVERSA(TM) Fentanyl. This meeting marks a critical phase in the regulatory process, bringing the company closer to introducing what could be the world's first abuse-deterrent opioid patch to the market.

Developed in collaboration with Kindeva, AVERSA(TM) Fentanyl integrates Nutriband's proprietary abuse-deterrent technology with Kindeva's FDA-approved fentanyl patch. This innovative approach aims to significantly reduce the risks of abuse, diversion, misuse, and accidental exposure, while ensuring that patients who genuinely need the medication retain access. The potential impact of this technology is substantial, with projected peak annual U.S. sales ranging between $80 million and $200 million, not to mention the planned expansion into global markets.

The significance of AVERSA(TM) Fentanyl extends beyond its commercial potential. In a time when the opioid crisis continues to devastate communities across the United States and beyond, the development of abuse-deterrent formulations represents a crucial step forward in public health efforts. Nutriband's technology, protected by patents in 46 countries, could set a new standard for the safe delivery of potent medications.

For more information on Nutriband Inc. and its groundbreaking work, visit https://www.nutriband.com. Additional updates and news regarding NTRB can be found at https://ibn.fm/NTRB.